Nestle invests $145m in biopharmaceutical firm Aimmune Therapeutics
Nestle Health Science is investing $145m for a 15% stake in Aimmune Therapeutics, a clinical-stage biopharmaceutical firm which develops treatments for people with life-threatening food allergies.
